ArticleFrontiers in immunology2026
Prognostic significance of calcium signaling-related genes in bladder cancer and the role of ATP2B4 in regulating mitochondrial calcium ion levels via the VDAC1/MCU pathway.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- SDF4: a novel prognostic biomarker and therapeutic target in hepatocellular carcinoma revealed by integrated multi‑omics analysis.Translational cancer research · 2026Article
- Bladder Cancer Biomarkers: Recent Advances in Early Detection, Treatment Prediction, and Prognosis.Oncology research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Calcium signaling, as a ubiquitous intracellular signal in eukaryotes, has been impacted in multiple biological processes encompassing tumorigenesis. Nevertheless, the integrated investigations on the function and prognostic value of genes correlated to calcium signaling in bladder cancer (BLCA) were still lacking. Methods: The transcriptome data and clinical data from BLCA patients were obtained from TCGA and GEO databases. Genes associated with calcium signaling that are differentially expressed in normal and malignant tissues were identified. Cox analysis and the least absolute shrinkage and selection operator (LASSO) analysis were employed to identify prognostic genes and develop a prognostic signature. The tuning parameter (λ) for LASSO regression was determined by cross-validation. The outcomes were then confirmed using an external independent dataset (GSE32894). The prognostic signature's reliability was assessed utilizing Kaplan-Meier, PCA, t-SNE, and ROC analyses. Furthermore, both univariate and multivariate Cox regression studies were undertaken to ensure if the prognostic signature functioned as an autonomous prognostic indication. Moreover, we examined the connection between the immune cell infiltration, the tumor mutation burden (TMB), and the prognostic signature. The Genomics of Drug Sensitivity in Cancer (GDSC) database and the IMvigor210 dataset were deployed to forecast the treatment reactions of the prognostic signature. Ultimately, the functionality of ATP2B4 was confirmed by Results: Thirty-two differentially expressed calcium signaling-correlated genes were identified in the TCGA dataset. A prognostic signature containing six genes (ATP2B4, BDKRB2, EDNRA, PDGFRA, EGFR, and ADCY7) was ascertained to anticipate the overall survival of BLCA. Furthermore, a nomogram containing risk scores with age was developed to anticipate the BLCA patient's prognosis. In addition, patients among the high- and low-risk groups displayed significant variation in TMB, immune infiltration landscape, and response to chemotherapy and immunotherapy. ATP2B4 has been recognized as a pivotal oncogenic gene. The suppression of ATP2B4 results in elevated cytoplasmic calcium ion(Ca Conclusions: Collectively, we have developed a unique genetic signature that is based on genes associated with calcium signaling. This signature possesses the capacity to precisely anticipate the survival prognosis and therapeutic response of BLCA patients and might have a crucial role in guiding clinical treatment. Furthermore, ATP2B4 has been identified as a crucial oncogenic gene. The downregulation of ATP2B4 leads to mitochondrial Ca
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.